AI drug discovery, protein modeling, digital twins and bioinformatics.
Computational modeling of biological systems — from molecular dynamics to systems biology at scale.
Machine learning models for target identification, compound screening and ADMET prediction.
Structure prediction, docking simulations and protein–protein interaction analysis.
Genomic, transcriptomic and proteomic data analysis pipelines for biomarker discovery.
Virtual patient and clinical trial simulations — accelerating regulatory submissions and reducing R&D costs.
High-performance computing infrastructure dedicated to life sciences workloads — GPU clusters and HPC nodes.
Danisei Digital is being developed as part of the I‑LACH Digital Biology initiative — an international research program advancing computational approaches to drug discovery and biology.
Traditional drug discovery takes over a decade and billions in investment. AI-driven platforms compress discovery timelines significantly and reduce early-stage failure rates through predictive modeling.
Virtual screening of vast compound libraries in days, not years.
AI-predicted toxicity reduces early-phase failure rates substantially.
Significant reduction in early discovery costs per clinical candidate.